Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Regulation of chemosensitivity in pancreatic cancer cells

ABSTRACT: Regulation of chemosensitivity in pancreatic cancer cells

PROVIDER: PRJNA784440 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17063404_1.fastq.gz	Fastqsanger.gz
	SRR17063404_2.fastq.gz	Fastqsanger.gz
	SRR17063405_1.fastq.gz	Fastqsanger.gz
	SRR17063405_2.fastq.gz	Fastqsanger.gz
	SRR17063406_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Regulation of chemosensitivity in pancreatic cancer cells

Project description:We performed RNA-seq to investigate gene expression changes in pancreatic cancer cells following chemotherapeutic drug treatment. We identify a reversible senescence state among the drug-tolerant persister cells.

2022-08-22 | GSE189764 | GEO

High-dose glutamine modulates amino acid transport and mediates pancreatic cancer chemosensitivity

Project description:High-dose glutamine modulates amino acid transport and mediates pancreatic cancer chemosensitivity

| PRJNA884815 | ENA

Pancreatic cancer cells treated with anlotinib

Project description:Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics and phosphoproteomics profiling) were carried to delineate the mechanism of anlotinib, a novel angiogenesis inhibitor, against pancreatic cancer cells.

2021-09-09 | PXD023344 | Pride

Combating pancreatic cancer with ovarian cancer cells

Project description:Combating pancreatic cancer with ovarian cancer cells

| PRJNA874314 | ENA

High-dose glutamine modulates amino acid transport and mediates pancreatic cancer chemosensitivity

Project description:We performed RNA-seq to investigate gene expression changes in pancreatic cancer cells following gemcitabine with high-dose L-Gln.

2022-09-30 | GSE214325 | GEO

H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma

Project description:H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma

| PRJNA530404 | ENA

Transcriptomic analysis of Pancreatic Stellate Cells (PSC) and pancreatic cancer cells

Project description:Transcriptomic analysis of Pancreatic Stellate Cells (PSC) and pancreatic cancer cells

| PRJNA434639 | ENA

Pancreatic cancer

Project description:Pancreatic cancer

| PRJNA1007691 | ENA

pancreatic cancer

Project description:pancreatic cancer

| PRJEB40742 | ENA

DAZAP2 controls cancer cell chemosensitivity by orchestrating the p53 response upon DNA damage

Project description:The tumor suppressors p53 and HIPK2 play a central role in cell fate decision-making upon DNA damage and regulate cancer cell chemosensitivity. Here we identify the adaptor protein Deleted in Azoospermia-associated protein 2 (DAZAP2) as a novel player in the DNA damage-induced p53 response. Knock-down or genetic deletion of DAZAP2 potentiates cancer cell chemosensitivity in vitro and in vivo. In unstressed cells, DAZAP2 stimulates HIPK2 ubiquitination and degradation through interaction with HIPK2 and the ubiquitin ligase SIAH1. After chemotherapeutic drug-induced DNA damage, DAZAP2 accumulates in the cell nucleus, which is regulated through site-specific phosphorylation by HIPK2. Nuclear DAZAP2 interacts with p53 response elements and specifies p53 target gene expression by modulating a select subset of p53 target genes. Mechanistically, DAZAP2 forms a complex with p53 and modulates target gene expression in association with HDAC1. Our findings identify DAZAP2 as a novel regulator of the p53 response and cancer cell chemosensitivity.

2021-02-10 | GSE154146 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data